April #69 : Vax Attack - by Shana Naomi Krochmal

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Geography Lessons

Mo' Money, Mo' Trouble

Cold Sore Comfort


Living Large on Small Change

Living Large on Small Change

Living Large on Small Change

O Pioneer!

Going Dental

Vax Attack

¡La Emergencia!

Monette & Merrill

Normal, New Jersey




Money Pit

Cryptic 'Script

Don't Meth Around

AAT Ease

Two Strikes


Is N-9 Deep-Sixed?

Action Zero

Mary MAC'd

Murphy's Law Breaker

Editor's Letter


04.09.84 The Waters of Babylon

Conflicts in Pharmaland

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

April 2001

Vax Attack

by Shana Naomi Krochmal

After spending a decade in a news hole, developments in vaccine R&D are replicating faster you can say "1 billion infected worldwide." Here's the recent buzz from the vax machine:

Because they have to give 5 percent to someone: The $21 billion Bill and Melinda Gates Foundation pledged another $100 million to HIV vax research through the New York City-based International AIDS Vaccine Initiative (IAVI). "There's no way commercial companies are going to see [an AIDS vaccine] as a priority," Bill Gates said by way of explanation. The so-called challenge grant is meant to spur other Midas-sized gifts from other megabucksters. (Reply to sender, Jeff Bezos!)

Dot-com redux: Yahoo! (www.yahoo.com) logged on as the first IAVI corporate sponsor with $5 million to be donated over three years: The web portal's worker bees will also help develop cyber campaigns to raise awareness of vax possibilities.

Not just for nerds: A high-tech vax that pairs the immune booster interleukin-2 (IL-2) with DNA could be helpful to HIVers. Harvard researchers found that the combo stimulated CD8 cell development in monkeys (see Data Dish, page 46).

A is for Africa: The first preventive vax specifically designed for Eastern Africa (where subtype A is the most common strain of HIV) began clinical trials at the University of Nairobi in February.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.